Population pharmacokinetics of carbamazepine in Chinese epilepsy patients.
OBJECTIVE
To investigate the pharmacokinetic profile of carbamazepine (CBZ) in Chinese epilepsy patients.


METHODS
Serum samples through concentrations at steady state (n = 687) were collected prospectively from 585 patients during routine clinical care. Data were analyzed by the non-linear mixed-effect modeling (NONMEM) technique with a one-compartment model of first-order absorption and elimination.


RESULTS
The important determinants of clearance (CL) were total body weight (TBW); dose; patient age over 65 years (E); and comedication with phenytoin (PHT), phenobarbital (PB), or valproic acid (VPA) when VPA daily dose was greater than 18 mg/kg. The final pharmacokinetic model for relative CL and apparent distribution volume (V) were: Equation


CONCLUSIONS
A population pharmacokinetic model was proposed to estimate the individual CL for Chinese patients receiving CBZ in terms of patient's dose, TBW, and comedications to establish a priori dosage regimens.
Jiao
Zheng
Z
Hua Shan Hospital, Fu Dan University, Shanghai, People's Republic of China.
Zhong
Ming-Kang
MK
Shi
Xiao-Jin
XJ
Hu
Min
M
Zhang
Jing-Hua
JH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002220:Carbamazepine / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D002681:China; D016001:Confidence Intervals; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D017711:Nonlinear Dynamics; D011446:Prospective Studies; D015203:Reproducibility of Results
D002220:Carbamazepine